Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares

Rhea-AI Summary

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) has priced its public offering of 2,686,409 common shares at $76.00 each, aiming for gross proceeds of approximately $200 million. The offering is expected to close on March 17, 2021, pending customary conditions. An underwriter option is included, allowing for an additional purchase of up to 402,961 shares. Goldman Sachs & Co. LLC acts as the book-running manager. The shares are issued under an effective shelf registration statement on Form S-3.

Positive

• Anticipated gross proceeds of approximately $200 million.
• Inclusion of a 30-day underwriter option for additional shares.

Negative

• Potential dilution of existing shareholders due to the new share issuance.

NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share.  In addition, Biohaven has granted the underwriter a 30-day option to purchase up to an additional 402,961 common shares at the public offering price, less underwriting discounts and commissions.  The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Biohaven.  The offering is expected to close on March 17, 2021, subject to satisfaction of customary closing conditions.

Goldman Sachs & Co. LLC is acting as the book-running manager of the offering.

The offering is being made only by means of a prospectus supplement and the accompanying prospectus, copies of which, when available, may be obtained from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1–866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com.

The shares will be issued pursuant to an effective shelf registration statement on Form S-3.  Copies of the registration statement can be accessed through the SEC's website at www.sec.gov.  This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

Contact

Dr. Vlad Coric

Chief Executive Officer

Biohaven Pharmaceutical Holding Company Ltd.

Phone: (203) 404-0410

Email: vlad.coric@biohavenpharma.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares-301247797.html

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

FAQ

What is the share price for Biohaven's recent offering?

Biohaven's recent public offering shares are priced at $76.00 each.

When is the expected closing date for Biohaven's offering?

The expected closing date for the offering is March 17, 2021.

What are the total proceeds Biohaven aims to raise from this offering?

Biohaven aims to raise approximately $200 million from this offering.

Who is managing Biohaven's public offering?

Goldman Sachs & Co. LLC is acting as the book-running manager for the offering.

How many additional shares can the underwriter purchase?

The underwriter has an option to purchase up to an additional 402,961 common shares.